Gilead Sciences, Inc.
NEWS
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
On May 5, the company issued a statement describing their efforts.
JOBS
IN THE PRESS